Advertisement
Advertisement

NDRA

NDRA logo

ENDRA Life Sciences Inc. Common Stock

4.00
USD
Sponsored
+0.21
+5.41%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

3.88

-0.12
-3.00%

NDRA Earnings Reports

Positive Surprise Ratio

NDRA beat 18 of 27 last estimates.

67%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.25
Implied change from Q3 25 (Revenue/ EPS)
--
/
-40.48%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-83.72%

ENDRA Life Sciences Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, NDRA reported earnings of -2.10 USD per share (EPS) for Q3 25, missing the estimate of -1.98 USD, resulting in a -5.58% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -1.25 USD, with revenue projected to reach -- USD, implying an decrease of -40.48% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Thermo Fisher Scientific, Inc.
Report Date
Jan 29, 2026 For Q4 25
Estimate
$6.51
Actual
$6.57
Surprise
+0.91%
logo
Idexx Laboratories Inc
Report Date
Feb 02, 2026 For Q4 25
Estimate
$2.98
Actual
$3.08
Surprise
+3.12%
logo
IQVIA Holdings Inc.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$3.43
Actual
$3.42
Surprise
-0.34%
logo
Mettler-Toledo International
Report Date
Feb 05, 2026 For Q4 25
Estimate
$12.92
Actual
$13.36
Surprise
+3.34%
logo
STERIS plc
Report Date
Feb 04, 2026 For Q3 26
Estimate
$2.55
Actual
$2.52
Surprise
-0.99%
logo
Hologic Inc
Report Date
Jan 29, 2026 For Q1 26
Estimate
$1.11
Actual
$1.04
Surprise
-6.45%
logo
Mesa Laboratories Inc
Report Date
Feb 03, 2026 For Q3 26
Estimate
$0.28
Actual
$3.07
Surprise
+987.88%
logo
Accuray Incorporated
Report Date
Feb 04, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+1.96%
FAQ
For Q3 2025, ENDRA Life Sciences Inc. Common Stock reported EPS of -$2.10, missing estimates by -5.58%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.46%, changed from $6.70 before the earnings release to $6.20 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 3 analysts, ENDRA Life Sciences Inc. Common Stock is expected to report EPS of -$1.25 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement